Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes.

Publication

Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes.

Journal Paper/Review - Jan 4, 2024

Smith Eric Edward, Shoamanesh Ashkan, Xu Lizhen, Heenan Laura, Saad Feryal, Colorado Pablo, Chen Chih-Hao, Lemmens Robin, De Marchis Gian Marco, Caso Valeria, Masjuan Jaime, Hirano Teruyuki, Milanov Ivan, Campbell Bruce C V, Mas Jean-Louis, Connolly Stuart J, Mundl Hardi, Hart Robert G, Kägi Georg

Citation

Smith E, Shoamanesh A, Xu L, Heenan L, Saad F, Colorado P, Chen C, Lemmens R, De Marchis G, Caso V, Masjuan J, Hirano T, Milanov I, Campbell B, Mas J, Connolly S, Mundl H, Hart R, Kägi G. Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes. Stroke 2024; 55:392-402.

Type

Journal Paper/Review (English)

Journal

Stroke 2024; 55

Publication Date

Jan 4, 2024

Issn Electronic

1524-4628

Pages

392-402

Brief description/objective

Exploratory analysis of the phase 2 PACIFIC-Stroke (Program of Anticoagulation via Inhibition of FXIa by the Oral Compound BAY 2433334-Non-Cardioembolic Stroke) randomized trial suggested that asundexian, an oral factor XIa inhibitor, prevents recurrent stroke and transient ischemic attacks in patients with atherosclerotic stroke. In this post hoc exploratory analysis, we hypothesized that asundexian would be more effective in patients enrolled with large, multiple, or cortical acute infarcts on magnetic resonance imaging than in patients enrolled with a single small subcortical acute infarct, and asundexian would prevent incident cortical covert infarcts.